EXECUTIVE TEAM


ZOË BARRY, FOUNDER & CEO

FOUNDER AND CEO

SANDY DICESARE

CHIEF OPERATING OFFICER

LESLIE HOYT

CHIEF GROWTH OFFICER

LIBBY CURTIS WEBB

SVP, PRODUCT

JONATHAN WEINRIEB

VP, HEAD OF LEGAL

KAREN TIROZZI

VP, SOLUTIONS

ZEESHAN KHAN

VP, PRODUCT DEVELOPMENT

Rich Kramer

VP, COMMERCIAL OPERATIONS

BOARD OF DIRECTORS


JENS ECKSTEIN

PRESIDENT, SRONE

MARK MCDADE

MANAGING PARTNER, QIMING US HEALTHCARE FUND

KRISHNA YESHWANT

PARTNER, GV (BOARD OBSERVER)

MIKE WYZGA

INDEPENDENT DIRECTOR AND BIOTECH CONSULTANT, MSW CONSULTING, INC.

JULIA AUSTIN

SENIOR LECTURER, HARVARD BUSINESS SCHOOL

JEREMY LEVIN

CEO AND CHAIRMAN, OVID THERAPEUTICS

JEFF BERKOWITZ

EXECUTIVE VICE PRESIDENT, UNITEDHEALTH GROUP

JAY SILVERSTEIN

CEO, PICWELL

KEVIN BITTERMAN

PARTNER, ATLAS VENTURE (BOARD OBSERVER)

ADVISORS


PETER WIRTH

SENIOR ADVISOR

SIMON KENNEDY

SENIOR ADVISOR

SCOTT MCKAY

ADVISOR

Competitive analysis

    • How many prescriptions were written for my brand? Other brands? By whom?

    • How many prescriptions were filled? Refilled?

    • Am I missing fills from when patients change insurance?


Time to Fill (TTF)

    • How quickly are my scripts being filled?

    • What and where are the bottlenecks?

    • What are payers doing to impact access? Pricing?


Real-world evidence

    • When, how, and why does my drug work?

    • What patients, biomarkers, and companion diagnoses predict performance?

    • How many prescriptions were abandoned by patients? Why?